麻豆传媒

ASCO: Low-Dose Radiation OK in CNS Lymphoma

CHICAGO -- Whole-brain radiation at about half the standard dose is safe and effective after chemotherapy for patients with primary central nervous system lymphoma, researchers are reporting.

May 31, 2012

ASCO: Abagovomab No Help in Ovarian Cancer

CHICAGO -- Results from a study using the experimental monoclonal antibody drug abagovomab to protect women with advanced ovarian cancer from recurrence have been disappointing, researchers reported here.

Jun 08, 2011

ASCO: Targeted Agent Slows Recurrent Ovarian Cancer

CHICAGO -- Women with recurrent platinum-sensitive ovarian cancer had a 50% improvement in progression-free survival when bevacizumab (Avastin) was added to chemotherapy, results of a multicenter randomized trial showed.

Jun 08, 2011

ASCO: Flaxseed No Help for Hot Flashes

CHICAGO -- Flaxseed will not ease hot flashes for women with menopausal symptoms or breast cancer survivors taking anti-estrogen drugs, according to clinical trial results.

Jun 08, 2011

ASCO: Methotrexate Boost Improves ALL Outcomes

CHICAGO -- There's new life in an old drug for high-risk acute lymphoblastic leukemia (ALL).

Jun 04, 2011

ASCO: Real-World Study Confirms Cervical Cancer Screening Guidelines

CHICAGO -- Screening for cervical cancer using Pap or HPV testing can safely take place every three years for women over 30, a researcher reported.

May 18, 2011

ASCO: Survival No Better After Axillary Node Surgery

CHICAGO -- Routine removal of axillary nodes in breast cancer patients with lymph node involvement does not improve survival or lessen the risk of relapse, a researcher said here.

Jun 08, 2010

ASCO: Value of RT After Lumpectomy Questioned

CHICAGO -- Postlumpectomy radiation therapy had minimal impact on outcomes in older patients with early-stage breast cancer, data from a larger intergroup trial showed.

May 21, 2010

ASCO: Cancer Survivors Get Benefit from Yoga

CHICAGO -- Gentle stretching, breathing, and other exercises in a regular yoga program may ease sleep and fatigue problems common among cancer survivors, a randomized trial found.

May 20, 2010

ASCO: Ginger Eases Chemo-Related Nausea

TORONTO -- Half a teaspoon of ground ginger a day can significantly reduce the nausea associated with chemotherapy, researchers found.

May 14, 2009

ASCO: Platinum-Taxane Regimen No Benefit for Thymoma or Thymic Carcinoma

CHICAGO -- For treatment-naive advanced thymoma or thymic carcinoma, carboplatin (Paraplatin) and paclitaxel (Taxol) failed to achieve response rates approaching those reported in published trials of athracycline-based regimens.

Jun 05, 2008

ASCO: Bevacizumab (Avastin) May Reduce Progression in Advanced Breast Cancer

CHICAGO -- In recurrent or metastatic breast cancer, bevacizumab (Avastin) significantly improved progression-free survival when added to docetaxel (Taxotere), a multicenter European study showed.

Jun 02, 2008

ASCO: In Endometrial Cancer, Less GI Toxicity with Brachytherapy than External-Beam

CHICAGO --Vaginal brachytherapy is as effective in preventing a recurrence of endometrial cancer after surgery in women with high-intermediate risk disease as external-beam pelvic radiotherapy but with less gastrointestinal toxicity, Dutch researchers reported here.

Jun 01, 2008

ASCO: High Dose Pemetrexed (Alimta) Fails to Increase Survival in NSCLC

CHICAGO -- Increasing the dose of pemetrexed (Alimta) to 900 mg/m2 did not improve outcome for patients with advanced non-small cell lung cancer (NSCLC), but did slightly increase toxicity, researchers found.

Jun 08, 2007

ASCO: Imatinib (Gleevec) After GIST Surgery Achieves Big Survival Advantage

CHICAGO -- Imatinib (Gleevec) after curative surgery for gastrointestinal stromal tumors (GIST) achieved a 90% two-year recurrence-free survival, investigators reported here.

Jun 06, 2007

ASCO: Vitamin B₁₂ Supplementation Can Be Given Closer to Pemetrexed for NSCLC

CHICAGO -- A shorter lead-in time between recommended vitamin B12 supplementation and pemetrexed (Alimta) therapy may reduce treatment delays without impairing its efficacy.

Jun 05, 2007